<DOC>
	<DOCNO>NCT01490437</DOCNO>
	<brief_summary>Pemetrexed demonstrate favorable response minimal toxicity use single agent first-line second-line treatment advance urothelial carcinoma . The response rate 32 % 28 % first-line second-line setting , respectively . Cisplatin one active chemotherapeutic agent urothelial cancer , frequently use combination chemotherapy GP ( gemcitabine plus cisplatin ) MVAC ( methotrexate , vinblastine , adriamycin , cisplatin ) . Pemetrexed cisplatin show favorable activity profile advance non-small cell lung cancer highly favorable toxicity profile . This study ass efficacy safety pemetrexed plus cisplatin advanced urothelial carcinoma .</brief_summary>
	<brief_title>Pemetrexed Cisplatin Advanced Urothelial Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Histologic cytologic diagnosis urothelial ( transitional cell ) carcinoma exception micropapillary subtype Patients must recurrent disease ( locally advance metastatic ) amenable local therapy newly diagnose distant metastatic disease Measurable disease define RECIST v.1.0 ECOG performance status 2 good Adequate organ bone marrow function define Other tumor type urothelial carcinoma Presence history CNS metastasis Prior systemic chemotherapy immunotherapy ( prior local intravesical chemotherapy immunotherapy allow . And recurrent disease adjuvant neoadjuvant cisplatinbased systemic chemotherapy allow last chemotherapy administer 1 year patient enrollment . ) Presence second primary malignancy ( except situ carcinoma cervix adequately treat basal cell carcinoma skin ) Peripheral sensory neuropathy grade 2 bad Other serious illness medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Advanced urothelial carcinoma</keyword>
</DOC>